GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » Shiller PE Ratio

Soligenix (STU:DOA) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Soligenix Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Soligenix Shiller PE Ratio Historical Data

The historical data trend for Soligenix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix Shiller PE Ratio Chart

Soligenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Soligenix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Soligenix's Shiller PE Ratio

For the Biotechnology subindustry, Soligenix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soligenix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Soligenix's Shiller PE Ratio falls into.



Soligenix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Soligenix's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Soligenix's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Soligenix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -5.520 100.560 -7.234
201409 -24.444 100.428 -32.074
201412 0.000 99.070 0.000
201503 -26.334 99.621 -34.834
201506 -20.047 100.684 -26.238
201509 -6.014 100.392 -7.894
201512 -10.190 99.792 -13.456
201603 -7.947 100.470 -10.423
201606 -2.537 101.688 -3.288
201609 -6.549 101.861 -8.472
201612 -1.991 101.863 -2.576
201703 -4.488 102.862 -5.750
201706 -5.474 103.349 -6.980
201709 -2.139 104.136 -2.707
201712 -3.422 104.011 -4.335
201803 -3.285 105.290 -4.111
201806 -2.311 106.317 -2.864
201809 -1.414 106.507 -1.749
201812 -2.373 105.998 -2.950
201903 -1.195 107.251 -1.468
201906 -1.593 108.070 -1.942
201909 -1.907 108.329 -2.320
201912 -1.890 108.420 -2.297
202003 -4.344 108.902 -5.256
202006 -1.332 108.767 -1.614
202009 -0.764 109.815 -0.917
202012 -2.343 109.897 -2.809
202103 -0.808 111.754 -0.953
202106 -0.623 114.631 -0.716
202109 -1.148 115.734 -1.307
202112 -1.081 117.630 -1.211
202203 -1.380 121.301 -1.499
202206 -0.785 125.017 -0.827
202209 -1.162 125.227 -1.223
202212 -1.237 125.222 -1.302
202303 -0.336 127.348 -0.348
202306 -0.203 128.729 -0.208
202309 -0.150 129.860 -0.152
202312 -0.147 129.419 -0.150
202403 0.000 131.776 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Soligenix  (STU:DOA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Soligenix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Soligenix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Soligenix (STU:DOA) Business Description

Traded in Other Exchanges
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines